CRL · 8-K · 20261104PR000156
Net Income and Profitability
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-11-04 · Importance 83 · Surprise 82 · From source text
Third-quarter GAAP net income attributable to common shareholders was $333.1 million, or $6.86 per diluted share, compared with $54.4 million, or $1.10, in 2025. The year-over-year increase included a $245.6 million, or $5.06 per-share, benefit from acquired tax-reserve reversals. Non-GAAP net income increased 24.8% to $150.1 million, and non-GAAP diluted EPS rose 27.2% to $3.09 from $2.43, primarily reflecting higher operating margin and a lower tax rate.
Key facts
- Third-quarter 2026 GAAP net income attributable to common shareholders was $333.1 million, or $6.86 per diluted share, versus $54.4 million, or $1.10 per diluted share, in third-quarter 2025. source
- Third-quarter 2026 non-GAAP net income was $150.1 million, up 24.8% from $120.3 million in third-quarter 2025. source
- Third-quarter 2026 non-GAAP diluted EPS was $3.09, up 27.2% from $2.43 in third-quarter 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | positive | realized | +27.8% | Third-quarter 2026 GAAP net income attributable to common shareholders was $333.1 million, or $6.86 per diluted share, versus $54.4… |